ClinicalTrials.gg

Program

cabazitaxel

Also written as “Cabazitaxel (XRP6258)”, “CABAZITAXEL (XRP6258)” and “Cabazitaxel”.

Its studies are mostly in Prostatic Neoplasms · Neoplasms · Nervous System Neoplasms · Small Cell Lung Carcinoma · Stomach Neoplasms, led by 3 companies.

Furthest: phase 4, since Jul 20, 201221 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi190 open or runningphase 4since Jul 20, 2012Dec 28, 2006none ahead
Bristol-Myers Squibb10 open or runningphase 2since Nov 22, 2016Nov 22, 2016none ahead
Jina Pharmaceuticals11 open or runningphase 2since Mar 17, 2025Mar 17, 2025Dec 2026phase 2 · NCT06890832

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Dec 28, 2006.

  1. Dec 2, 2010Phase 3 study in Prostate Cancer MetastaticSanofi · NCT01254279 · 984 enrolled · Australia, Austria, Belgium and more
  2. Mar 3, 20112 phase 3 studies in Prostatic NeoplasmsSanofi · NCT01308580, NCT01308567
  3. Mar 22, 2011Phase 1 study in Prostatic NeoplasmsSanofi · NCT01324583 · 48 enrolled · Japan
  4. Dec 6, 20112 phase 2 studiesSanofi · NCT01497964, NCT01500720
  5. Feb 2, 2012Phase 1 study in NeoplasmsSanofi · NCT01527929 · 25 enrolled · Belgium, Italy, Netherlands and more
  6. Mar 30, 2012Phase 2 study in Prostatic NeoplasmsSanofi · NCT01576029 · 2 enrolled · Brazil
  7. Jul 20, 2012Phase 4 study in Prostatic NeoplasmsSanofi · NCT01649635 · 45 enrolled · Brazil
  8. Oct 29, 2012Phase 2 study in Prostate Cancer MetastaticSanofi · NCT01718353 · 63 enrolled · United States, Canada
  9. Dec 13, 2012Phase 2 study in Malignant Solid Tumor - Malignant Nervous System NeoplasmSanofi · NCT01751308 · 39 enrolled · United States, Canada
  10. Dec 17, 2012Phase 1 study in Advanced Solid TumorSanofi · NCT01755390 · 42 enrolled · France, Spain
  11. Feb 27, 2015Phase 2 study in Prostate Cancer MetastaticSanofi · NCT02379390 · 8 enrolled · United States, Canada
  12. Jun 26, 2015Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02485691 · 255 enrolled · Austria, Belgium, Czechia and more
  13. Nov 22, 2016Bristol-Myers Squibb's first study: phase 2 study in Prostatic NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02985957 · 351 enrolled · United States, Australia, Austria and more
  14. Mar 17, 2025Jina Pharmaceuticals's first study: phase 2 study in Metastatic Castration-resistant Prostate Cancer, MCRPCNew to Jina PharmaceuticalsJina Pharmaceuticals · NCT06890832 · 75 planned

Ahead

  1. Dec 2026Primary completion: phase 2 study in Metastatic Castration-resistant Prostate Cancer, MCRPCJina Pharmaceuticals · NCT06890832

TargetBeta

“Tubulin inhibitor”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
DocetaxelruleSanofiphase 4199
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06890832Metastatic Castration-resistant Prostate Cancer, MCRPC2Not yet recruitingJina PharmaceuticalsDec 202675
NCT02985957Prostatic Neoplasms · United States, Australia, Austria and more2CompletedBristol-Myers SquibbApr 5, 2022351
NCT02485691Prostate Cancer Metastatic · Austria, Belgium, Czechia and more4CompletedSanofiMar 27, 2019255
NCT02379390Prostate Cancer Metastatic · United States, Canada2TerminatedSanofiMay 10, 20188
NCT01755390Advanced Solid Tumor · France, Spain1CompletedSanofiAug 200242
NCT01751308Malignant Solid Tumor - Malignant Nervous System Neoplasm · United States, Canada2CompletedSanofiJul 201539
NCT01718353Prostate Cancer Metastatic · United States, Canada2CompletedSanofiAug 201563
NCT01649635Prostatic Neoplasms · Brazil4CompletedSanofiJan 201445
NCT01576029Prostatic Neoplasms · Brazil2CompletedSanofiDec 20132
NCT01527929Neoplasms · Belgium, Italy, Netherlands and more1CompletedSanofiNov 201325
NCT01500720Small Cell Lung Carcinoma · United States, Brazil, Canada and more2CompletedSanofiApr 2014179
NCT01497964Stomach Neoplasms · Korea, Republic of2CompletedSanofiMay 201316
NCT01324583Prostatic Neoplasms · Japan1CompletedSanofiNov 201448
NCT01308580Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedSanofiAug 20151,200
NCT01308567Prostatic Neoplasms · United States, Australia, Belarus and more3CompletedSanofiSep 20151,168
NCT01254279Prostate Cancer Metastatic · Australia, Austria, Belgium and more3CompletedSanofiDec 2014984
NCT01140607Neoplasms · United States1CompletedSanofiJul 201456
NCT01087021Neoplasms · United States, Belgium, Denmark and more1CompletedSanofiApr 201145
NCT01001221Neoplasms · United States2TerminatedSanofiOct 201119
NCT00925743Solid Cancer · United States1CompletedSanofiMar 201376
NCT00417079Neoplasms · United States, Argentina, Belgium and more3CompletedSanofiSep 2009755

How it is read

Names in the registry

  • “Cabazitaxel (XRP6258)”, 7 entries
  • “CABAZITAXEL (XRP6258)”, 3 entries
  • “Cabazitaxel”, 2 entries
  • “cabazitaxel XRP6258”, 2 entries
  • “Cabazitaxel XRP6258”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.